検索結果

Management Policy | About Senju | SENJU Pharmaceutical

ecessary and valuable for society, we are committed to pursuing happiness for all people associated with Senju rather than just becoming a “big company” that pursues only greater growth and increased ...

ry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designe...

ry Eye Disease (DED), has been launched in Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designe...

Management Policy | About Senju | SENJU Pharmaceutical

ecessary and valuable for society, we are committed to pursuing happiness for all people associated with Senju rather than just becoming a “big company” that pursues only greater growth and increased ...

re safer and more reliable use. For this approval, a bioequivalence study was conducted on patients with primary open-angle glaucoma or ocular hypertension, confirming that the new formulation has the...